8-K/A: Wellgistics Licenses AI Smart Contract IP for PharmacyChain

Wellgistics Health secures exclusive license from DataVault AI for blockchain-enabled smart contracts to revolutionize prescription drug distribution.

Summary

• Wellgistics Health, Inc. entered into a license agreement with DataVault AI Inc. on November 24, 2025, to license intellectual property for developing manufacturer-to-patient blockchain-enabled smart contracts, known as "PharmacyChain."
• PharmacyChain aims to optimize Wellgistics' proprietary technology and physical infrastructure for the prescription drug industry by fully digitizing the tracking of prescription drugs from script to fulfillment.
• The initiative is designed to integrate with Wellgistics' recently completed EinsteinRx AI hub, which connects over 6,500 independent pharmacies nationwide and an in-house pharmacy.
• A primary objective is to reduce significant rebates paid by drug manufacturers to Pharmacy Benefit Managers (PBMs), which are commonly cited as a reason for high US prescription drug prices.
• Wellgistics intends to attract employers, HMOs, and other payers by offering greater visibility, transparency, and efficiency in prescription fulfillment through its pharmacy network.
• The license term is for the life of DataVault's underlying patents, unless earlier terminated by the parties.

Sentiment

Score: 8

Explanation: The filing details a strategic licensing agreement that could significantly enhance Wellgistics' market position and disrupt the pharmaceutical distribution industry. The potential for increased efficiency, cost reduction, and improved patient outcomes, backed by exclusive IP, is highly positive. However, the substantial upfront fee and ongoing royalty obligations represent financial commitments that need to be managed.

Positives

• Secures exclusive intellectual property rights for blockchain-enabled smart contracts, providing a barrier to entry in the healthcare market.
• Positions Wellgistics to become a leader in Web 3.0 health information data transfer within the $634 billion US prescription drug industry.
• Enables the integration of the EinsteinRx AI hub with PharmacyChain to optimize prescription fulfillment and potentially revolutionize pharmaceutical distribution.
• Aims to significantly improve cost and efficiency of prescription filling, reduce costs for payers, and lower retail drug prices.
• Expected to improve patient outcomes and provide better data to manufacturers.
• Potential to minimize or eliminate PBM rebates for pharmacies and manufacturers, reducing administrative burden for payers.
• Opportunity to empower patients to monetize their health data, potentially reducing out-of-pocket costs.

Negatives

• Wellgistics must pay a non-refundable license fee of $2,500,000.00 to DataVault by December 31, 2025.
• A royalty fee of 13% on all net profit received from the use of the license must be paid monthly to DataVault.
• A minimum annual royalty of $1,000,000 is required for calendar year 2028 and each year thereafter, with specific conditions for 2028 and 2029 (Wellgistics must achieve $2,000,000 annual net profit from PharmacyChain for the minimum to apply).
• If Wellgistics sublicenses the materials, 90% of all net revenue received from such sublicenses must be remitted to DataVault quarterly.

Risks

• Forward-looking statements are subject to risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied.
• Certain factors that could cause actual future results to differ materially are noted in connection with such statements, but other unanticipated factors could arise.
• Risks regarding forward-looking statements are discussed in Wellgistics' filings with the SEC, including an extensive discussion in its Registration Statement on Form S-1, declared effective on September 25, 2025.
• The Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of the Form 8-K or to reflect the occurrence of unanticipated events, conditions, or circumstances.

Future Outlook

Wellgistics intends to become the US leading smart contract-enabled pharmaceutical distribution platform by integrating its EinsteinRx AI hub onto the PharmacyChain platform. The company expects to accelerate efforts to integrate EinsteinRx into customer workflows and develop an optimal digital protocol that could become the industry standard. This strategy aims to minimize or eliminate PBM rebates, reduce administrative burden for payers, and potentially reduce patient out-of-pocket costs by enabling data monetization.

Management Comments

• "Web 3.0 smart contracts are the future of secure data transfer that allow for the automation of key functions to more quickly close loops that slow down the conduct of the business in the $4.9 trillion healthcare industry." Nathaniel Bradley, President & CEO of DataVault AI.
• "We're thrilled about the prospect of significantly improving the cost and efficiency of prescription filling, reducing costs for payers while helping lower retail drug prices, improving patient outcomes, and providing better data to the manufacturer." Nathaniel Bradley, President & CEO of DataVault AI.
• "Now that we have completed EinsteinRx, we are poised to put it on the PharmacyChain digitally-enabled smart contract platform and intend to become the US leading smart contract-enabled pharmaceutical distribution platform." Prashant Patel, RPh, President & Interim CEO of Wellgistics.
• "With defensible IP now backing our go-to-market strategy, we will accelerate our efforts to integrate EinsteinRx into our customers workflow." Prashant Patel, RPh, President & Interim CEO of Wellgistics.
• "By minimizing or eliminating PBM rebates for pharmacies and manufacturers while reducing administrative burden for payers, Wellgistics intends to disrupt and revolutionize the path through which prescription drugs are dispensed in the United States." Prashant Patel, RPh, President & Interim CEO of Wellgistics.
• "Further, given our CTO Srini Kallas background at OptumRX, we possess all the ingredients necessary to develop new ways to reduce patients out-of-pocket costs by empowering them with the ability to monetize their data to manufacturers or other stakeholders within the healthcare system." Prashant Patel, RPh, President & Interim CEO of Wellgistics.

Industry Context

This agreement positions Wellgistics at the forefront of integrating Web 3.0 and AI technologies into the traditional pharmaceutical distribution landscape. It directly addresses the long-standing issue of high prescription drug prices in the US, often attributed to the complex rebate system involving Pharmacy Benefit Managers (PBMs). By leveraging blockchain-enabled smart contracts, Wellgistics aims to increase transparency and efficiency, potentially disrupting the current PBM-dominated model. This aligns with broader industry trends towards digital transformation, personalized healthcare, and reducing administrative burdens, as highlighted by PwC's estimated $1 trillion opportunity in digital-first healthcare. The move could reshape how manufacturers, pharmacies, physicians, patients, and payers interact within the $634 billion prescription drug industry and the larger $4.9 trillion US healthcare market.

Comparison to Industry Standards

• The initiative aims to disrupt the current PBM-dominated model, which is often criticized for contributing to high prescription drug prices in the US, a stark contrast to many global healthcare systems with more regulated pricing.
• The integration of Web 3.0 smart contracts and AI (EinsteinRx) for prescription fulfillment optimization positions Wellgistics at the cutting edge, moving beyond traditional, less transparent distribution methods.
• The focus on digitizing the entire prescription tracking process from script to fulfillment, including electronic medical records, seeks to establish a new standard for data integrity and patient safety, potentially surpassing current fragmented systems.
• The goal of empowering patients to monetize their health data represents an innovative approach to patient engagement and cost reduction, a concept not widely implemented in the current healthcare landscape.

Stakeholder Impact

• Shareholders: Potential for significant long-term value creation through market disruption, increased revenue, and improved profitability, but also immediate financial obligations (license fee, royalties).
• Patients: Expected benefits include lower retail drug prices, improved patient outcomes, better data for safe and effective use, and the ability to monetize their health data to reduce out-of-pocket costs.
• Pharmacies (6,500+ independent pharmacies in network): Potential for reduced administrative burden and minimized/eliminated PBM rebates, leading to improved profitability and operational efficiency.
• Manufacturers: Benefits from better data, potentially reduced PBM rebates, and a more efficient distribution channel.
• Payers (Employers, HMOs, Insurance Companies): Greater visibility, transparency, and efficiency in prescription fulfillment, leading to reduced costs.
• Employees: Potential for growth and expansion of the company, possibly leading to new opportunities.

Next Steps

• Wellgistics to pay DataVault AI a non-refundable license fee of $2,500,000.00 by December 31, 2025.
• Wellgistics will accelerate efforts to integrate EinsteinRx into customer workflows.
• Wellgistics intends to implement various steps to ensure the creation of an optimal digital protocol for the commercial prescription drug distribution industry.
• Wellgistics will continue to develop new ways to reduce patients' out-of-pocket costs by empowering them to monetize their data.

Key Dates

Recommendation

This filing outlines a highly strategic and potentially transformative move for Wellgistics Health. Securing exclusive intellectual property for blockchain-enabled smart contracts in the prescription drug industry, combined with their existing EinsteinRx AI hub and extensive pharmacy network, positions the company for significant disruption in a multi-trillion-dollar market. The stated goals of reducing PBM rebates, lowering drug prices, improving patient outcomes, and enabling patient data monetization address critical pain points in the US healthcare system. While there are substantial upfront and ongoing costs associated with the license, the potential for market leadership and long-term value creation in a high-growth sector makes this a strong buy signal for investors with a long-term horizon, despite the inherent risks of innovation and execution.

Keywords

Wellgistics Health, DataVault AI, PharmacyChain, EinsteinRx, smart contracts, blockchain, prescription drugs, pharmaceutical distribution, health IT, Web 3.0, AI, PBMs, healthcare technology, intellectual property licensing